Navigation Links
Tianyin Corporate Presentation Updated
Date:9/23/2010

CHENGDU, China, Sept. 23 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a biopharmaceutical company that specializes in modernized traditional Chinese medicine, branded generics and other pharmaceuticals, publishes the updated corporate presentation which was presented at 2010 Roth Hawaii Conference and Rodman & Renshaw 2010 Annual Global Investment Conference in September at the Company's website:

www.tianyinpharma.com

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that is engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics, equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin achieved 10 new drug approvals at SFDA in 2009 and has a pipeline of 10 products pending regulatory approval that target various indications with considerable market potential. Tianyin has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerDirectorTianyin Pharmaceutical Co., Inc.Web:
http://www.tianyinpharma.comEmail:
Dr.Tong@tianyinpharma.comTel:
+86-28-8551-6696 (Chengdu, China)+1-949-350-6999 (U.S.)+86-134-3655-0011 (China)Address: 23rd Floor Unionsun Yangkuo PlazaNo 2 Block 3 South Renmin RoadChengdu, 610041China
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
2. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
3. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
4. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
5. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
6. Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET
7. Tianyin Promotes its Flagship Product Portfolio at the 45th 2010 National New Special Drugs Trade Fair in July at Beijing
8. Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Genta Incorporated Announces Third Quarter 2007 Financial Results
11. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... TapImmune, Inc. (NASDAQ: TPIV), ... of innovative peptide and gene-based immunotherapeutics for the ... that it will participate in two upcoming Investor ... Wilson , Chairman and CEO of TapImmune, will ... pipeline and partnering opportunities for its proprietary PolyStart ...
(Date:3/22/2017)... , March 22, 2017 Hologic, Inc. ... has completed the acquisition of Cynosure, Inc., a leader ... share in cash. "We are pleased to ... working with Michael Davin and the entire ... large, rapidly growing medical aesthetics market," said Steve ...
(Date:3/22/2017)... 2017 TFS is pleased to announce the ... Tumaian , two global executive positions in Medical Affairs and Clinical ... Leadership Team and will report to Dr. Montse Barceló , ... ... 10 years of medical and scientific expertise gained across leading biopharmaceutical ...
Breaking Medicine Technology:
(Date:3/22/2017)... San Antonio, TX (PRWEB) , ... March 22, ... ... ISO certified medical imaging core lab with extensive therapeutic experience and operational excellence ... multi-year phase II immuno-oncology clinical trial for the treatment of non-small cell lung ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... and financial consultations to families and business owners in the greater Hampton Roads ... local American Cancer Society Relay For Life event. , Each year, hundreds of ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... and related services to communities across eastern Texas, is announcing a charity drive ... meals to hungry children and adults. , Consistently a top-rated nonprofit organization ...
(Date:3/22/2017)... ... March 22, 2017 , ... Schneider Insurance and Financial, ... business owners throughout the Yellowstone Valley region, is launching a charity event aimed at ... botanical garden in all of Montana State, and is home to a broad variety ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Chris Humphrey Insurance ... families and business professionals throughout the coastal plains region, is initiating a charity event ... cancer. , Dillyn was first diagnosed with leukemia on a Friday evening in September ...
Breaking Medicine News(10 mins):